Wednesday, April 20 Scientific Platform Sessions 6:30 a.m.–8:30 a.m. Scientific Platform Sessions S36: Update in Muscle Disorders 6:30 a.m. S36.001 Anti-cN1A Autoantibody Seropositivity Is Associated with Increased Mortality Risk in Inclusion Body Myositis —James Lilleker, Anke Rietveld (joint first author), Umesh Badrising, Olivier Benveniste, Karina Gheorghe, Michael Hanna, Megan Herbert, David Hilton-Jones, Janine Lamb, Bryan Lecky, Ingrid Lundberg, Pedro Machado, Kubéraka Mariampillai, James Miller, Matt Parton, Maikel Peeters, Stephen Pye, Mark Roberts, Sabrina Sacconi, Christiaan Saris, Robert Cooper, Ger Pruijn, Hector Chinoy, Baziel van Engelen 6:45 a.m. S36.002 Limb Girdle Muscular Dystrophy Due to Calpainopathy Also Exists in a Dominantly Inherited Form —John Vissing, Rita Barresi, Nanna Witting, Marijke van Ghelue, Laurence Bindoff, Straub Volker, Hanns Lochmuller, Christoph Wahl, Christoffer Jonsrud, Morten Duno 7:00 a.m. S36.003 Disease-Specific Splicing Changes Are Seen in Children with Congenital Myotonic Dystrophy —Donald McCorquodale, Katie Mayne, Diane Dunn, Brith Otterud, Nicholas Johnson, Robert Weiss 7:15 a.m. S36.004 A Novel Glycogenin-1 Gene Mutation in a Family with Late-onset Proximal Myopathy —Corrado Angelini, Marina Fanin, Vincenzo Nigro, Annalaura Torella, Marco Savarese 7:30 a.m. S36.005 Silencing of Myotonic Dystrophy Protein Kinase (DMPK) Does Not Affect Cardiac or Muscle Function in Mice —Samuel Carrell, Ellie Carrell, David Auerbach, Sanjay Pandey, Frank Bennett, Robert Dirksen, Charles Thornton 7:45 a.m. S36.006 Electrical Impedance Myography Is Reliable and Correlates to Measures of Facioscapulohumeral Muscular Dystrophy Disease Severity —Jeffrey Statland, Chad Heatwole, Katy Eichinger, Nuran Dilek, William Martens, Alrabi Tawil 8:00 a.m. S36.007 Exercise Training Normalizes Mitochondrial Function in Myopathies Due to Heteroplasmic Mitochondrial DNA (mtDNA) Mutations —Ronald Haller 8:15 a.m. S36.008 Revisiting the Clinical, Histochemical and Molecular Spectrum of Adult- Onset AdPEO Associated with the C10Orf2 (PEO1) Mutation —Grainne Gorman, Kate Craig, Carl Fratter, Yi Shiau Ng, Andrew Purvis, Robert Field, Emma Blakely, Joanna Poulton, Robert McFarland, Doug Turnbull, Robert Taylor S37: Risk Factors for Multiple Sclerosis 6:30 a.m. S37.001 Dietary Intake of Sodium and Other Minerals and the Risk of Multiple Sclerosis —Marianna Cortese, Tanuja Chitnis, Alberto Ascherio, Kassandra Munger 6:45 a.m. S37.002 Increased Sodium Intake Is Not Associated with MS Activity or Progression in BENEFIT —Kathryn Fitzgerald, Kassandra Munger, Mark Freedman, Hans Hartung, Xavier Montalban, Gilles Edan, Frederik Barkhof, Ernst-Wilhelm Radue, Ludwig Kappos, Gustavo Suarez, Alberto Ascherio 7:00 a.m. S37.003 Smoking Cessation Decelerates Brain Volume Loss in Patients with Multiple Sclerosis —Navid Seraji-Bozorgzad, Fen Bao, Sara Razmjou, Christina Caon, Alexandros Tselis, Carla Santiago Martinez, Imad Zak, Evanthia Bernitsas, Omar Khan 7:15 a.m. S37.004 Physical Comorbidities Are Associated with an Increased Risk of Psychiatric Comorbidity in Multiple Sclerosis — Ruth-Ann Marrie, Scott Patten, Jamie Greenfield, Helen Tremlett, Christina Wolfson, Sharon Warren, Larry Svenson, Nathalie Jette, John Fisk 7:30 a.m. S37.005 Multiple Sclerosis Lesions Show Perturbations in Cerebral Microbiota — William Branton, Jian Lu, Michael Surette, Robert Holt, John Lind, Jon Laman, Christopher Power 7:45 a.m. S37.006 Novel Multiple Sclerosis Genetic Risk Factors Are Involved in Epigenetic Regulation —Dorothea Buck, Till Andlauer, Antonios Bayas, Klaus Berger, Achim Berthele, Elisabeth Binder, Theresa Dankwoski, Andre Franke, Ralf Gold, Stefan Herms, Georg Homuth, Karl-Heinz Joeckel, Tim Kacprowski, Bernd Kieseier, Tania Kuempfel, Matthias Laudes, Wolfgang Lieb, Volker Limmroth, Ralf Linker, Susanne Moebus, Martina Mueller-Nurasyid, Antonella Mulas, Markus Noethen, Friedemann Paul, Martin Stangel, Jan- Patrick Stellmann, Konstantin Strauch, Bjorn Tackenberg, Florian Then Bergh, Hayrettin Tumani, Frank Weber, Peter Weber, Heinz Wiendl, Brigitte Wildemann, Uwe Zettl, Andreas Ziegler, Ulf Ziemann, Frauke Zipp, Francesco Cucca, Bertram Müller-Myhsok, Bernhard Hemmer 8:00 a.m. S37.007 Grey Matter Lesion Signature of Multiple Sclerosis —Jun-ichi Satoh, Yoshihiro Kino 8:15 a.m. S37.008 Multiple Sclerosis Clinical Characteristics in Molecularly- Defined Patient Populations —Ahmed Enayetallah, Raghavendra Hosur, Richard Ransohoff, Jaya Goyal S38: General Neurology: Therapeutics 6:30 a.m. S38.001 Edaravone, a Free Radical Scavenger, Delays Symptomatic and Pathological Progression of Wobbler Mouse Motor Neuron Disease —Ken Ikeda, Yasuo Iwasaki 6:45 a.m. S38.002 Hematopoietic Stem Cell Transplantation in Late-Onset Krabbe Disease Halts Demyelination and Axonal Loss: A 4-Year Longitudinal Case Study —Cornelia Laule, Elham Shahinfard, Burkhard Mӓdler, Irene Vavasour, Jing Zhang, Ritu Aul, David Li, Alex MacKay, Sandra Sirrs 7:00 a.m. S38.003 Phase 2 Open-Label Extension Study (OLE) of Patisiran, an Investigational RNAi Therapeutic for Familial Amyloid Polyneuropathy (FAP)—David Adams, Teresa Coelho, Isabel Conceicao, Marcia Waddington-Cruz, Hartmut Schmidt, Juan Buades, Josep Campistol, Jean Pouget, John Berk, Rick Falzone, Lindsey White, Brian Bettencourt, Jeff Cehelsky, Sara Nochur, Akshay Vaishnaw, Kirsten Gruis, Jared Gollob, Ole Suhr 7:15 a.m. S38.004 Functional and Imaging Studies of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-350 in a Clinically Relevant Murine Model of Closed Head Injury (CHI) —Claire Drolen, Haichen Wang, Talaignair Venkatraman, Chuan Fang, Yanli Tan, Sharon Tamir, Sharon Shacham, Christopher Lascola, Daniel Laskowitz 7:30 a.m. S38.005 Phase 1 Safety and Pharmacokinetics of the Novel Enzyme Replacement Therapy NeoGAA in Treatment-Naïve and Alglucosidase Alfa-Treated Late- Onset Pompe Disease Patients —Jaya Trivedi, Ans Van Der Ploeg, Richard Barohn, Barry Byrne, Claude Desnuelle, Ozlem Goker-Alpan, Shafeeq Ladha, Pascal Laforet, Eugen Mengel, Alan Pestronk, Jean Pouget, Benedikt Schoser, Volker Straub, Philip Van Damme, John Vissing, Peter Young, Raheel Shafi, Kerry Culm- Merdek, Gerard Short, Loren Pena, and the NeoGAA Investigator Group 7:45 a.m. S38.006 Phase 1 Exploratory Efficacy of the Novel Enzyme Replacement Therapy NeoGAA in Treatment-Naïve and Alglucosidase Alfa-Treated Late-Onset Pompe Disease Patients —Loren Pena, Richard Barohn, Barry Byrne, Claude Desnuelle, Ozlem Goker-Alpan, Shafeeq Ladha, Pascal Laforet, Eugen Mengel, Alan Pestronk, Jean Pouget, Benedikt Schoser, Volker Straub, Jaya Trivedi, Philip Van Damme, John Vissing, Peter Young, Beth Thurberg, Kerry Culm-Merdek, Gerard Short, Ans van der Ploeg, and the NeoGAA Investigator Group 8:00 a.m. S38.007 The Effect of Bolus Volume and Mechanical Forces on the Biodistribution of ASOs Following Lumbar Intrathecal Administration in Cynomolgus Monkeys —Daniel Wolf, Jenna Sullivan, Curt Mazur, Eric Swayze, Berit Powers, Jack Hoppin, Ajay Verma 8:15 a.m. S38.008 Kinetics of ASO Distribution and Pharmacodynamics in the CNS After an Intrathecal Bolus Dose in Rat —Eric Swayze, Berit Powers, Fredrik Kamme, Curt Mazur, Daniel Wolf, Jenna Sullivan, Ajay Verma $ A registration fee is required L The program is one of the AAN Leadership University sessions S The course is part of a Subspecialty in Focus track I The program is one of the I Talk sessions Learning Lab Excitement of Discovery Health & Wellness Real World of Neurology The program is part of the Experiential Learning Area sessions 110 2016 AAN Annual Meeting Abstract Listing
Meeting Schedule 6:30 a.m.–8:30 a.m. S36 Update in Muscle Disorders S37 Risk Factors for Multiple Sclerosis S38 General Neurology: Therapeutics C166 S Acute Neurological Emergencies Director: Paul Alan Nyquist, MD, MPH, Baltimore, MD C167 S Current State of Alzheimer’s Disease Imaging Biomarkers and the Road Ahead Director: Liana Apostolova, MD, FAAN, Indianapolis, IN C168 Clinical E-Pearls Director: Robert M. Pascuzzi, MD, FAAN, Indianapolis, IN C169 Clinical Epilepsy I Director: Tracey A. Milligan, MD, FAAN, Boston, MA C170 Principles of Genomic Medicine: Clinical Exome Sequencing in Neurologic Disease Director: Brent L. Fogel, MD, PhD, Los Angeles, CA C171 Management of Behavioral Disturbances in Dementias Director: Maria Kataki, MD, PhD, Columbus, OH C172 Neuro Flash: Neuro-ophthalmology Director: Valerie Biousse, MD, Atlanta, GA C173 Therapy of Movement Disorders: A Case-based Approach Director: Stephen G. Reich, MD, FAAN, Baltimore, MD C174 Clinical EMG I Director: Ruple S. Laughlin, MD, Rochester, MN C175 The Interface Between Infection and Cerebrovascular Disease Director: Reza Behrouz, DO, San Antonio, TX C176 Therapy of Headache Director: Stephanie J. Nahas, MD, FAAN, Philadelphia, PA 8:00 a.m.–9:00 a.m. I Telemovement Demonstration Directors: Eric Anderson, MD, PhD, Decatur, GA Jaime Hatcher-Martin, MD, Atlanta, GA 8:30 a.m.–7:00 p.m. P5 Poster Session V . . . . . . . . . . . . . . . . 112 9:00 a.m.–11:00 a.m. Clinical Trials Plenary Session . . . . . . . . . . 123 11:00 a.m.–4:00 p.m. Exhibit Hall 1:00 p.m.–2:00 p.m. I Personalized Neurogenomic Medicine Director: Joseph J. Higgins, MD, FAAN, Marlborough, MA Health & Wellness Integrating Management of Activity and Exercise in Routine Clinical Practice Director: Lisa M. Shulman, MD, Baltimore, MD I Talks Offer Dynamic, Interactive Learning Location: Room 110 I Talks are dynamic, one-hour programs at the 2016 AAN Annual Meeting that promote innovation, audience participation, and interaction. Learn how to get the most out of the AAN’s apps and online resources; join discussions about the latest standards for measuring quality in neurology and hot-topic ethical issues physicians are facing today; and participate in social media Q+A’s and a live neurology exam. Live, real-time intraoperative monitoring will demonstrate the growing importance of the use of telemedicine and include discussion of how live patient interactions are set up. Learn more at AAN.com/view/ITalks. Wed· April 20
Change language